公开(公告)号：US20200254090A1

公开(公告)日：2020-08-13

申请号：US15774327

申请日：2016-11-09

Applicant: Novartis AG

Inventor： Shinji Hatakeyama ,  Ronenn Roubenoff ,  Estelle Trifilirff ,  Jerome Feige ,  Lloyd B Klickstein

IPC: A61K39/395 ,  A61P35/00 ,  A61P21/00 ,  A61K33/243 ,  A61K31/436

Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.

公开(公告)号：US09623012B2

公开(公告)日：2017-04-18

申请号：US14770819

申请日：2014-02-26

Applicant: Novartis AG

Inventor： Miloud Achour ,  Robin Alec Fairhurst ,  Arnaud Grandeury ,  Shinji Hatakeyama ,  Magdalena Koziczak-Holbro ,  Nicola Tufilli ,  Thomas Ullrich

IPC: A61K31/428 ,  A61K31/19 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61K31/428 ,  A61K9/0053 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/19

Abstract: The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

公开(公告)号：US09913828B2

公开(公告)日：2018-03-13

申请号：US15178579

申请日：2016-06-10

Applicant: Novartis AG

Inventor： Jun Cao ,  Bernhard Erb ,  Robin Alec Fairhurst ,  Arnaud Grandeury ,  Shinji Hatakeyama ,  Magdalena Koziczak-Holbro ,  Xinzhong Lai ,  Philipp Lustenberger ,  Bernd Ulrich Riebesehl ,  Nicola Tufilli ,  Thomas Ullrich ,  Xiang Wu ,  Jianguang Zhou

IPC: A61K31/428 ,  C07D277/68 ,  A61K45/06 ,  A61K31/167 ,  C07C53/10

CPC classification number: A61K31/428 ,  A61K31/167 ,  A61K45/06 ,  C07B2200/07 ,  C07C53/10 ,  C07D277/68 ,  Y02P20/55

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

公开(公告)号：US11357851B2

公开(公告)日：2022-06-14

申请号：US15774327

申请日：2016-11-09

Applicant: Novartis AG

Inventor： Shinji Hatakeyama ,  Ronenn Roubenoff ,  Estelle Trifilieff ,  Jerome Feige ,  Lloyd B. Klickstein

IPC: A61K39/395 ,  A61P21/00 ,  A61P35/00 ,  A61K33/243 ,  A61K31/436

Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.

公开(公告)号：US10251868B2

公开(公告)日：2019-04-09

申请号：US15876619

申请日：2018-01-22

Applicant: NOVARTIS AG

Inventor： Jun Cao ,  Bernhard Erb ,  Robin Alec Fairhurst ,  Arnaud Grandeury ,  Shinji Hatakeyama ,  Magdalena Koziczak-Holbro ,  Xinzhong Lai ,  Philipp Lustenberger ,  Bernd Ulrich Riebesehl ,  Nicola Tufilli ,  Thomas Ullrich ,  Xiang Wu ,  Jianguang Zhou

IPC: A61K31/428 ,  A61K31/167 ,  C07D277/68 ,  C07C53/10 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.